IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide to target T cells that recognize epitopes derived from Arginase 1, which is an immunoregulatory enzyme highly expressed in difficult-to-treat tumors associated with high levels of myeloid-derived suppressor cells, including renal cell carcinoma, head and neck, breast, pancreatic, ovarian, colorectal, and prostate cancers. In addition, the company develops IO170, a TGFß1 vaccine for the treatment of solid tumors. IO Biotech, Inc. was incorporated in 2014 and is based in Copenhagen, Denmark.
तुलना करने के लिए मीट्रिक्स | IOBT | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधIOBTपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −0.3x | −9.0x | −0.5x | |
PEG अनुपात | −0.11 | −0.13 | 0.00 | |
क़ीमत/बुक | 27.6x | 2.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 12.9x | 3.3x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 252.5% | 45.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | −11.8% | 5.8% | अनलॉक करें |